Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
0.7330
-0.0821 (-10.07%)
At close: May 14, 2025, 4:00 PM
0.7512
+0.0182 (2.48%)
After-hours: May 14, 2025, 6:53 PM EDT
Sutro Biopharma Stock Forecast
STRO's stock price has decreased by -82.67% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for Sutro Biopharma stock ranges from a low of $1.00 to a high of $15. The average analyst price target of $6.14 forecasts a 737.65% increase in the stock price over the next year.
Price Target: $6.14 (+737.65%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Sutro Biopharma stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 1 | 1 | 1 |
| Buy | 4 | 4 | 4 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 3 | 4 | 4 |
| Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $2 | Hold | Reiterates | $2 | +172.85% | Apr 29, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $12 → $2 | Strong Buy → Hold | Downgrades | $12 → $2 | +172.85% | Mar 17, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Mar 14, 2025 |
| Wedbush | Wedbush | Buy → Hold Downgrades $8 → $2 | Buy → Hold | Downgrades | $8 → $2 | +172.85% | Mar 14, 2025 |
| B of A Securities | B of A Securities | Strong Buy → Sell Downgrades $11 → $1 | Strong Buy → Sell | Downgrades | $11 → $1 | +36.43% | Mar 14, 2025 |
Financial Forecast
Revenue This Year
48.09M
from 62.04M
Decreased by -22.49%
Revenue Next Year
48.71M
from 48.09M
Increased by 1.29%
EPS This Year
-2.24
from -2.96
EPS Next Year
-1.39
from -2.24
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 79.4M | 96.8M | 169.5M | ||
| Avg | 48.1M | 48.7M | 60.9M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 28.0% | 101.4% | 248.0% | ||
| Avg | -22.5% | 1.3% | 25.1% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.76 | -0.21 | -0.01 | ||
| Avg | -2.24 | -1.39 | -1.31 | ||
| Low | -2.69 | -3.19 | -2.54 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.